Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors

References

• Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29:591 - 9; http://dx.doi.org/10.1200/JCO.2010.31.0904; PMID: 21220598
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• O’Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD. Cancer immunoediting of the NK group 2D ligand H60a. J Immunol 2011; 187:3538 - 45; http://dx.doi.org/10.4049/jimmunol.1100413; PMID: 21876033
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730 - 7; http://dx.doi.org/10.1038/nm0797-730; PMID: 9212098
   PubMed Web of Science ®Google Scholar
• Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394:1098 - 104; http://dx.doi.org/10.1016/j.bbrc.2010.03.138; PMID: 20350531
   PubMed Web of Science ®Google Scholar
• Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147:614 - 33; http://dx.doi.org/10.1111/j.1365-2141.2009.07886.x; PMID: 19735262
   PubMed Web of Science ®Google Scholar
• Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2011; http://dx.doi.org/10.1038/bmt.2011.202; PMID: 21986635
   PubMed Web of Science ®Google Scholar
• Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012; 14:91 - 103; http://dx.doi.org/10.3109/14653249.2011.613931; PMID: 21973023
   PubMed Web of Science ®Google Scholar
• Tan AC, Konczak I, Sze DM, Ramzan I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 2011; 63:495 - 505; http://dx.doi.org/10.1080/01635581.2011.538953; PMID: 21500099
   PubMed Web of Science ®Google Scholar
• Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010; 10:238; http://dx.doi.org/10.1186/1471-2407-10-238; PMID: 20504360
   PubMed Web of Science ®Google Scholar
• He X, Wang Y, Zhu J, Orloff M, Eng C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett 2011; 301:168 - 76; http://dx.doi.org/10.1016/j.canlet.2010.11.012; PMID: 21168265
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström’s macroglobulinemia. Clin Cancer Res 2008; 14:1849 - 58; http://dx.doi.org/10.1158/1078-0432.CCR-07-1750; PMID: 18347188
   PubMed Web of Science ®Google Scholar
• Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol 2010; 37:258 - 81; http://dx.doi.org/10.1053/j.seminoncol.2010.06.014; PMID: 20709209
   PubMed Web of Science ®Google Scholar
• Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio G, et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2005; 115:36 - 45; http://dx.doi.org/10.1002/ijc.20874; PMID: 15688416
   PubMed Web of Science ®Google Scholar
• Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. Life Sci 2001; 70:81 - 96; http://dx.doi.org/10.1016/S0024-3205(01)01367-4; PMID: 11764009
   PubMed Web of Science ®Google Scholar
• Zunino SJ, Storms DH. Resveratrol alters proliferative responses and apoptosis in human activated B lymphocytes in vitro. J Nutr 2009; 139:1603 - 8; http://dx.doi.org/10.3945/jn.109.105064; PMID: 19549761
   PubMed Web of Science ®Google Scholar
• Lu CC, Chen JK. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol 2010; 223:343 - 51; PMID: 20082299
   PubMed Web of Science ®Google Scholar
• Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, et al. Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol 2011; 11:1877 - 86; http://dx.doi.org/10.1016/j.intimp.2011.07.019; PMID: 21854876
   PubMed Web of Science ®Google Scholar
• She M, Niu X, Chen X, Li J, Zhou M, He Y, et al. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett 2011; http://dx.doi.org/10.1016/j.canlet.2011.12.017; PMID: 22198207
   PubMed Web of Science ®Google Scholar
• Tang Z, Liu XY, Zou P. Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells. J Huazhong Univ Sci Technolog Med Sci 2007; 27:508 - 12; http://dx.doi.org/10.1007/s11596-007-0508-0; PMID: 18060622
   PubMed Web of Science ®Google Scholar
• Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 2009; 28:3221 - 34; http://dx.doi.org/10.1038/onc.2009.183; PMID: 19561642
   PubMed Web of Science ®Google Scholar
• Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 2011; 137:279 - 86; http://dx.doi.org/10.1007/s00432-010-0884-x; PMID: 20401667
   PubMed Web of Science ®Google Scholar
• Kartal M, Saydam G, Sahin F, Baran Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer 2011; 63:637 - 44; http://dx.doi.org/10.1080/01635581.2011.538485; PMID: 21500096
   PubMed Web of Science ®Google Scholar
• Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011; 6:e16530; http://dx.doi.org/10.1371/journal.pone.0016530; PMID: 21304978
   PubMed Web of Science ®Google Scholar
• Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 2011; 130:387 - 98; http://dx.doi.org/10.1007/s10549-010-1300-6; PMID: 21188630
   PubMed Web of Science ®Google Scholar
• Li T, Wang W, Chen H, Li T, Ye L. Evaluation of anti-leukemia effect of resveratrol by modulating STAT3 signaling. Int Immunopharmacol 2010; 10:18 - 25; http://dx.doi.org/10.1016/j.intimp.2009.09.009; PMID: 19796711
   PubMed Web of Science ®Google Scholar
• Luzi C, Brisdelli F, Cinque B, Cifone G, Bozzi A. Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells. Biochem Pharmacol 2004; 68:2019 - 30; http://dx.doi.org/10.1016/j.bcp.2004.07.002; PMID: 15476673
   PubMed Web of Science ®Google Scholar
• Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM, Zou JP. Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 2002; 23:893 - 7; PMID: 12370094
   PubMed Web of Science ®Google Scholar
• Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011; 60:575 - 86; http://dx.doi.org/10.1007/s00262-010-0965-3; PMID: 21240486
   PubMed Web of Science ®Google Scholar
• Correia MP, Costa AV, Uhrberg M, Cardoso EM, Arosa FA. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 2011; 216:604 - 12; http://dx.doi.org/10.1016/j.imbio.2010.09.012; PMID: 20956026
   PubMed Web of Science ®Google Scholar
• Bae JH, Kim JY, Kim MJ, Chang SH, Park YS, Son CH, et al. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother 2010; 33:391 - 401; http://dx.doi.org/10.1097/CJI.0b013e3181d32f22; PMID: 20386467
   PubMed Web of Science ®Google Scholar
• González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29:397 - 403; http://dx.doi.org/10.1016/j.it.2008.04.007; PMID: 18602338
   PubMed Web of Science ®Google Scholar
• Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J Jr.. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 2008; 10:1402 - 10; PMID: 19048119
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27:5932 - 43; http://dx.doi.org/10.1038/onc.2008.267; PMID: 18836474
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 2009; 58:1275 - 85; http://dx.doi.org/10.1007/s00262-008-0645-8; PMID: 19139882
   PubMed Web of Science ®Google Scholar
• Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008; 14:3520 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-07-4744; PMID: 18519785
   PubMed Web of Science ®Google Scholar
• Tang KF, Ren H, Cao J, Zeng GL, Xie J, Chen M, et al. Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol 2008; 182:233 - 9; http://dx.doi.org/10.1083/jcb.200801169; PMID: 18644891
   PubMed Web of Science ®Google Scholar
• Qiao Y, Liu B, Li Z. Activation of NK cells by extracellular heat shock protein 70 through induction of NKG2D ligands on dendritic cells. Cancer Immun 2008; 8:12; PMID: 18613644
   PubMedGoogle Scholar
• Molinero LL, Fuertes MB, Girart MV, Fainboim L, Rabinovich GA, Costas MA, et al. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol 2004; 173:5583 - 90; PMID: 15494508
   PubMed Web of Science ®Google Scholar
• Tokuyama M, Lorin C, Delebecque F, Jung H, Raulet DH, Coscoy L. Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathog 2011; 7:e1002265; http://dx.doi.org/10.1371/journal.ppat.1002265; PMID: 21966273
   PubMedGoogle Scholar
• Zauli G, Bosco R, Secchiero P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011; 15:931 - 42; http://dx.doi.org/10.1517/14728222.2011.580278; PMID: 21548717
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42:501 - 10; http://dx.doi.org/10.1016/j.molimm.2004.07.034; PMID: 15607806
   PubMed Web of Science ®Google Scholar
• Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011; 60:1173 - 80; http://dx.doi.org/10.1007/s00262-011-1008-4; PMID: 21626033
   PubMed Web of Science ®Google Scholar
• Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4′, 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal 2007; 2:7; http://dx.doi.org/10.1186/1750-2187-2-7; PMID: 17718901
   PubMedGoogle Scholar
• Rushworth SA, Micheau O. Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer. Br J Pharmacol 2009; 157:1186 - 8; http://dx.doi.org/10.1111/j.1476-5381.2009.00266.x; PMID: 19664138
   PubMed Web of Science ®Google Scholar
• Jacquemin G, Shirley S, Micheau O. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?. Cell Mol Life Sci 2010; 67:3115 - 30; http://dx.doi.org/10.1007/s00018-010-0407-6; PMID: 20508968
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Tadokoro Y, Hirao A. Molecular pathology of tumor-initiating cells: lessons from Philadelphia chromosome-positive leukemia. Pathol Int 2011; 61:501 - 8; http://dx.doi.org/10.1111/j.1440-1827.2011.02688.x; PMID: 21884299
   PubMed Web of Science ®Google Scholar
• Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 2011; 22:799 - 806; http://dx.doi.org/10.1016/j.jnutbio.2010.11.001; PMID: 21295962
   PubMed Web of Science ®Google Scholar
• Buss EC, Ho AD. Leukemia stem cells. Int J Cancer 2011; 129:2328 - 36; http://dx.doi.org/10.1002/ijc.26318; PMID: 21796620
   PubMed Web of Science ®Google Scholar